“The applications of lentiviral vectors are diverse,” she says, pointing out that while 65% of the CDMO’s customers are developing immunotherapies, like CAR-Ts, TCRs, NK-CARs, NK-TCRs, TILs ...

In this GEN webinar, our expert panelists will discuss how they aim to develop technologies to improve Lentiviral vector yields and scalability. Specifically, we will hear about the challenges ...

The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

Bluebird bio has now secured FDA approvals for two lentiviral vector gene therapies for rare diseases. Melissa Bonner, the company’s head of research, discusses the rocky road to success and ...

Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In Vivo CAR-T Technology Platform made ...

Lentigen’s lentiviral gene therapy assets were acquired by German company Miltenyi Biotec in 2014. “Now is the perfect time to launch our business,” Dropulić said in a prepared statement.

Download this application note to receive step-by-step guidance about optimizing and standardizing scalable lentiviral vector production and clarification. Sponsored by. Top Image Credit: ©iStock, ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...

Discover how innovative production and clarification products improve lentiviral vector generation. Share. The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies.. The latest entry into the CDMO viral vector ...

GAITHERSBURG, Md., May 2, 2025 /PRNewswire/ -- Vector BioMed (VBM), a leading lentiviral vector CDMO advancing access to gene therapies, will showcase its innovations at two major industry events ...